<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="57366"><DrugName>formoterol fumarate (inhaled nebulized, COPD), Mylan</DrugName><DrugNamesKey><Name id="42970433">Perforomist</Name><Name id="42753934">eformoterol</Name><Name id="42753933">formoterol</Name><Name id="42753939">formoterol fumarate</Name><Name id="42970078">formoterol fumarate (USAN)</Name></DrugNamesKey><DrugSynonyms><Name><Value>formoterol</Value><Types><Type>INN</Type></Types></Name><Name><Value>eformoterol</Value><Types><Type>BAN</Type></Types></Name><Name><Value>formoterol fumarate</Value><Types><Type>USAN</Type></Types></Name><Name><Value>formoterol fumarate (inhaled nebulized, COPD), Mylan</Value></Name><Name><Value>formoterol fumarate (USAN)</Value><Types><Type>USAN</Type></Types></Name><Name><Value>Perforomist</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>formoterol fumarate dihydrate</Value></Name><Name><Value>73573-87-2</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="18113">Mylan Specialty</CompanyOriginator><CompaniesPrimary><Company id="18113">Mylan Specialty</Company></CompaniesPrimary><CrossReferences><SourceEntity id="18113" type="Company"><TargetEntity id="5000709871" type="organizationId">Mylan Specialty LP</TargetEntity></SourceEntity><SourceEntity id="111" type="ciIndication"><TargetEntity id="J43" type="ICD10"/><TargetEntity id="492" type="ICD9"/><TargetEntity id="10014561" type="MEDDRA"/><TargetEntity id="D004646" type="MeSH"/><TargetEntity id="-1329111132" type="omicsDisease"/><TargetEntity id="282" type="siCondition"/></SourceEntity><SourceEntity id="1185" type="ciIndication"><TargetEntity id="10009033" type="MEDDRA"/><TargetEntity id="D029424" type="MeSH"/><TargetEntity id="-459670493" type="omicsDisease"/><TargetEntity id="277" type="siCondition"/></SourceEntity><SourceEntity id="1488" type="ciIndication"><TargetEntity id="10006458" type="MEDDRA"/><TargetEntity id="D029481" type="MeSH"/><TargetEntity id="-1358226401" type="omicsDisease"/><TargetEntity id="280" type="siCondition"/></SourceEntity><SourceEntity id="40" type="Action"><TargetEntity id="60" type="Mechanism">beta2-Adrenoceptor Agonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-00073" type="ciTarget"><TargetEntity id="9354386111543" type="siTarget">Beta-2 adrenergic receptor</TargetEntity><TargetEntity id="878" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Chronic bronchitis - US - Oct-2007</FirstLaunched><FirstLaunched>Chronic obstructive pulmonary disease - US - Oct-2007</FirstLaunched><FirstLaunched>Emphysema - US - Oct-2007</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="111">Emphysema</Indication><Indication id="1185">Chronic obstructive pulmonary disease</Indication><Indication id="1488">Chronic bronchitis</Indication></IndicationsPrimary><ActionsPrimary><Action id="40">Beta 2 adrenoceptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="1470">Respiratory system agent</Action><Action id="646">Bronchodilator</Action></ActionsSecondary><Technologies><Technology id="617">Aerosol formulation inhalant</Technology><Technology id="616">Inhalant formulation</Technology><Technology id="746">Solution</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>R3A</Code><Name>B2-STIMULANTS</Name></Ephmra><Ephmra><Code>R</Code><Name>RESPIRATORY SYSTEM</Name></Ephmra></EphmraCodes><LastModificationDate>2018-02-27T09:27:43.000Z</LastModificationDate><ChangeDateLast>2018-02-23T00:00:00.000Z</ChangeDateLast><AddedDate>2007-05-21T13:06:06.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="18113" linkType="Company"&gt;Mylan Specialty&lt;/ulink&gt; (formerly Dey Pharma;  previously a subsidiary of &lt;ulink linkID="18101" linkType="Company"&gt;MerckKGaA&lt;/ulink&gt;; now a subsidiary of &lt;ulink linkID="18439" linkType="Company"&gt;Mylan&lt;/ulink&gt;), has developed and launched Perforomist, a twice-daily nebulized formulation of the long-acting beta 2 agonist (LABA) &lt;ulink linkID="6140" linkType="Drug"&gt;formoterol fumarate&lt;/ulink&gt;. The drug is indicated in the US for long-term, twice daily (morning and evening) administration in the  maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema [&lt;ulink linkID="1755984" linkType="Reference"&gt;1755984&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2007, the drug was launched in the US [&lt;ulink linkID="837101" linkType="Reference"&gt;837101&lt;/ulink&gt;], [&lt;ulink linkID="837042" linkType="Reference"&gt;837042&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;In October 2002, &lt;ulink linkID="PA168843" linkType="Patent"&gt;WO-02083113&lt;/ulink&gt;Â was published,  which claimed the use of novel aqueous compositions of formoterol, its derivatives and steroidal anti-inflammatory agents, stable to long-term storage and nebulized suspensions, for prophylactic or therapeutic use in bronchoconstrictive disorders, including asthma, chronic bronchitis and COPD. In the US, nebulized formoterol fumarate is covered by composition and method of use patents &lt;ulink linkID="PA174980" linkType="Patent"&gt;US-06667344&lt;/ulink&gt; and &lt;ulink linkID="PA174981" linkType="Patent"&gt;US-06814953&lt;/ulink&gt;, which expire in June 2021 and May 2022, respectively [&lt;ulink linkID="1263171" linkType="Reference"&gt;1263171&lt;/ulink&gt;]. In January 2009,  Dey was issued &lt;ulink linkID="PA3521882" linkType="Patent"&gt;US-07462645&lt;/ulink&gt;, &lt;ulink linkID="PA3524579" linkType="Patent"&gt;US-07465756&lt;/ulink&gt; and &lt;ulink linkID="PA3524574" linkType="Patent"&gt;US-07473710&lt;/ulink&gt;, all equivalent to &lt;ulink linkID="PA2941119" linkType="Patent"&gt;WO-2005007142&lt;/ulink&gt;, covering formoterol fumarate for COPD; the patents all expire in July 2024 [&lt;ulink linkID="975810" linkType="Reference"&gt;975810&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2007, &lt;ulink linkID="18113" linkType="Company"&gt;Dey&lt;/ulink&gt; (a subsidiary of Mylan) served Sepracor (now &lt;ulink linkID="19858" linkType="Company"&gt;Sunovion&lt;/ulink&gt;) a complaint alleging that &lt;ulink linkID="9100" linkType="Drug"&gt;arformoterol&lt;/ulink&gt; infringed a  US patent  owned by Dey. Sepracor filed a counterclaim seeking to invalidate the originally asserted patent and a second related patent. In May 2007, Dey filed a reply asserting infringement of the second patent. By March 2008, a trial was scheduled to begin no earlier than October 2009. In January 2009, Dey filed a motion to add all three of these patents to the case, which was not opposed by Sepracor [&lt;ulink linkID="882314" linkType="Reference"&gt;882314&lt;/ulink&gt;], [&lt;ulink linkID="1000931" linkType="Reference"&gt;1000931&lt;/ulink&gt;]. In March 2012, the US District Court granted partial summary judgment in favor of Sunovion regarding one of its defenses and the request to limit damages. At that time, Mylan planned to appeal against the decision and also intended to continue to pursue an injunction on two of its re-examined patents  [&lt;ulink linkID="1268293" linkType="Reference"&gt;1268293&lt;/ulink&gt;]. In May 2012, Sunovion settled its litigation with Mylan; under the settlement agreement, Sunovion acknowledged that arformoterol infringed Mylan's patents [&lt;ulink linkID="1294277" linkType="Reference"&gt;1294277&lt;/ulink&gt;], [&lt;ulink linkID="1294405" linkType="Reference"&gt;1294405&lt;/ulink&gt;]. In May 2013, the Court of Appeals for the Federal Circuit reversed the District Court's decision that had invalidated five of Mylan's Perforomist patents [&lt;ulink linkID="1424938" linkType="Reference"&gt;1424938&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2009, &lt;ulink linkID="20348" linkType="Company"&gt;Teva Pharmaceutical Industries&lt;/ulink&gt; filed an ANDA with a Paragraph IV certification for a generic version of Perforomist. In June 2009, Dey filed a US lawsuit against Teva alleging patent infringement of the US-06667344, US-06814953, &lt;ulink linkID="PA2938835" linkType="Patent"&gt;US-07348362&lt;/ulink&gt; and US-07462645 patents covering Perforomist [&lt;ulink linkID="1896645" linkType="Reference"&gt;1896645&lt;/ulink&gt;]. In July 2013, a District Court granted a motion for partial summary judgment finding that Teva's generic version of Perforomist infringed one of Mylan's patents (US-06667344). Trial on the remaining issues in the case was scheduled to begin later that month [&lt;ulink linkID="1453948" linkType="Reference"&gt;1453948&lt;/ulink&gt;]. In April 2015, a US Court of Appeals upheld the validity and infringement of all four patents asserted by Mylan,  affirming a previous decision by the District Court against Teva and preventing Teva from selling a generic version until June 2021 [&lt;ulink linkID="1652158" linkType="Reference"&gt;1652158&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In May 2007, the FDA approved Dey's nebulized formoterol fumarate NDA for twice-daily long-term maintenance treatment of bronchoconstriction foremphysema and chronic bronchitis (COPD) [&lt;ulink linkID="797064" linkType="Reference"&gt;797064&lt;/ulink&gt;]. The drug was approved as a 505b2 NDA, cross referencing formoterol in support of safety and efficacy [&lt;ulink linkID="794255" linkType="Reference"&gt;794255&lt;/ulink&gt;]. In October 2007, Dey and its commercialization partner, &lt;ulink linkID="30201" linkType="Company"&gt;Critical Therapeutics&lt;/ulink&gt;, launched the drug in the US [&lt;ulink linkID="837101" linkType="Reference"&gt;837101&lt;/ulink&gt;], [&lt;ulink linkID="837042" linkType="Reference"&gt;837042&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;SAFETY INFORMATION&lt;/subtitle&gt;In February 2011, a risk evaluation and mitigation strategy (REMS) was approved, requiring an analysis of patients' understanding of the increased risk of asthma-related deaths and safe use of LABAs. In September 2012, the FDA released the drug from its REMS because the REMS had met its goals [&lt;ulink linkID="1453236" linkType="Reference"&gt;1453236&lt;/ulink&gt;]. The US label carries a black box warning highlighting the increased risk of asthma-related death [&lt;ulink linkID="1263171" linkType="Reference"&gt;1263171&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;In May 2017, clinical data from a multi-center, randomized, double-blind, placebo-controlled, noninferiority study were presented from 1071 patients at the ATS International Conference in Washington DC. Patients were treated with nebulized perforomist (20 microg/2 ml, bid) or placebo. Patients who had completed the one-year treatment period were 520; treatment discontinuations were observed in 45.7 versus 57.4% of patients in Perforomist versus placebo groups, respectively. The median treatment duration for the Perforomist and placebo groups was approximately 10 and 7 months, respectively. Respiratory deaths (primary endpoint) were not observed in the Perforomist group, while one death (due to pneumonia) was observed in the placebo group. At month 3 and 6, significantly improved forced expiratory volume in 1 second was observed with Perforomist when compared with placebo (p &amp;lt;0.01 and &amp;lt;0.03), while did not observed at 9 or 12 months [&lt;ulink linkID="1929656" linkType="Reference"&gt;1929656&lt;/ulink&gt;]. Â In October 2017, further data were presented at the 2017 CHEST Conference in Toronto, Canada. Perforomist exhibited numerically greater improvements in all spirometry endpoints from baseline compared with the placebo group at all visits during the study. Least square mean differences between Perforomist and placebo were statistically significant (p &amp;lt;/= 0.05) for trough FEV1 (42 and 41 ml at 3 and 6 months, respectively), forced vital capacity (92, 90, 92, and 92 ml at 3, 6, 9, and 12 months, respectively), and %FEV1 (1.76, 1.70, and 1.51% at 3, 6, and 9 months, respectively) [&lt;ulink linkID="2000526" linkType="Reference"&gt;2000526&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In May 2009, pooled data from two trials assessing the addition of Perforomist to maintenance &lt;ulink linkID="8165" linkType="Drug"&gt;tiotropium&lt;/ulink&gt; therapy in 285 subjects with moderate-to-very severe COPD were reported at the American Thoracic Society meeting in San Diego, CA. At week 6, a 192 ml improvement was seen for the primary endpoint of absolute FEV1 AUC0-3 in the combination therapy arm. The combination also improved transitional dyspnia score, decreased rescue albuterol use and improved symptom domain score in a respiratory questionnaire. Other respiratory questionable scores were similar in the two arms. Adverse events were less frequent in the combination therapy arm. At the same meeting, data were reported showing that Perforomist improved patients satisfaction, compared with &lt;ulink linkID="44297" linkType="Drug"&gt;ipratropium&lt;/ulink&gt;/albuterol in 109 patients with moderate-to-severe disease [&lt;ulink linkID="1011211" linkType="Reference"&gt;1011211&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2007, results from a 569-patient, open-label, active-control, long-term safety study was presented at CHEST 2007, Chicago, IL. Moderate-to-severe COPD patients received either 20 microg Perforomist or 12 microg of dry powder inhaler of the same compound  for 12 months. The drug was well tolerated with adverse events and electrocardiogram results similar between the two groups [&lt;ulink linkID="843538" linkType="Reference"&gt;843538&lt;/ulink&gt;]. In May 2008, similar data were presented at the International conference of the American Thoracic Society in Toronto, Canada [&lt;ulink linkID="907973" linkType="Reference"&gt;907973&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2007, a multicenter, comparative, randomized, open-label, active-controlled, phase III trial (&lt;ulink linkID="3642" linkType="Protocol"&gt;NCT00462540&lt;/ulink&gt;; 201-081) was initiated in subjects (n = 100) with COPD in the US. The subjects were to receive either 2 ml of Perforomist or 1.8 ml of &lt;ulink linkID="44297" linkType="Drug"&gt;ipratropium bromide&lt;/ulink&gt; plus 1.03 ml of albuterol sulfate. The primary endpoint was improvement in lung function following 2 weeks of treatment. The study was completed in October 2007  [&lt;ulink linkID="797073" linkType="Reference"&gt;797073&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2007, data from a pivotal phase III trial for COPD were presented at the International Conference of the American Thoracic Society in San Francisco, CA. Patients in the 12-week, multicenter, randomized, double-blind study were treated twice-daily with either 2 ml of Perforomist (n = 123), the active comparator formoterol (n = 114) or placebo (n = 114). The data showed Perforomist to be significantly superior compared with placebo, meeting the trial's primary endpoint. The treatment provided rapid bronchodilation that persisted for 12 h, enabled patients to use less rescue medication (albuterol) and maintained lung function improvements with no evidence of tolerance. Fewer COPD exacerbations were seen in Perforomist-treated patients compared with placebo [&lt;ulink linkID="796839" linkType="Reference"&gt;796839&lt;/ulink&gt;]. In October 2007, further results were presented in CHEST 2007, Chicago, IL. Extensive cardiac safety monitoring showed that  Perforomist was not associated with an increased incidence of cardiovascular events [&lt;ulink linkID="843538" linkType="Reference"&gt;843538&lt;/ulink&gt;], [&lt;ulink linkID="843537" linkType="Reference"&gt;843537&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2007, a randomized, double-blind, active control, US, phase III trial (&lt;ulink linkID="4378" linkType="Protocol"&gt;NCT00507234&lt;/ulink&gt;; 201-080) was initiated in 128 patients aged 40 years and over with COPD. The 6 week trial would compare the safety and efficacy of 20 microg of Perforomist twice daily plus 18 microg of &lt;ulink linkID="8165" linkType="Drug"&gt;tiotropium&lt;/ulink&gt; once daily with tiotropium alone. The primary endpoint would be AUC over a 3 h assessment period at the end of the study [&lt;ulink linkID="837309" linkType="Reference"&gt;837309&lt;/ulink&gt;]. In May 2008, data from the trial were presented at the International conference of the American Thoracic Society in Toronto, Canada. Perforomist administered concomitantly with tiotropium was found to be significantly more effective than tiotropium alone [&lt;ulink linkID="907971" linkType="Reference"&gt;907971&lt;/ulink&gt;], [&lt;ulink linkID="907910" linkType="Reference"&gt;907910&lt;/ulink&gt;]. In October 2008, data from the phase IIIb trial were presented at CHEST, 2008 at Philadelphia, PA. Patients receiving Perforomist reported a greater satisfaction and an increased perception that medication went into the lungs when compared with patients in the albuterol or ipratopium arms. Patients in all treatment arms showed improvement in dyspnea [&lt;ulink linkID="957296" linkType="Reference"&gt;957296&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="18113">Mylan Specialty</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1488">Chronic bronchitis</Indication><StatusDate>2007-10-08T00:00:00.000Z</StatusDate><Source id="833332" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18113">Mylan Specialty</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="111">Emphysema</Indication><StatusDate>2007-10-08T00:00:00.000Z</StatusDate><Source id="833332" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18113">Mylan Specialty</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1185">Chronic obstructive pulmonary disease</Indication><StatusDate>2007-10-08T00:00:00.000Z</StatusDate><Source id="833332" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="18113">Mylan Specialty</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="111">Emphysema</Indication><StatusDate>2007-05-11T00:00:00.000Z</StatusDate><Source id="797064" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18113">Mylan Specialty</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1488">Chronic bronchitis</Indication><StatusDate>2007-05-11T00:00:00.000Z</StatusDate><Source id="797064" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18113">Mylan Specialty</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1185">Chronic obstructive pulmonary disease</Indication><StatusDate>2007-03-31T00:00:00.000Z</StatusDate><Source id="837309" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18113">Mylan Specialty</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1185">Chronic obstructive pulmonary disease</Indication><StatusDate>2007-05-11T00:00:00.000Z</StatusDate><Source id="797064" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00073"><Name>Beta 2 adrenoceptor</Name><SwissprotNumbers><Swissprot>O70431</Swissprot><Swissprot>P04274</Swissprot><Swissprot>P07550</Swissprot><Swissprot>P10608</Swissprot><Swissprot>P18762</Swissprot><Swissprot>P54833</Swissprot><Swissprot>Q28044</Swissprot><Swissprot>Q28509</Swissprot><Swissprot>Q28997</Swissprot><Swissprot>Q8UUY8</Swissprot><Swissprot>Q9TST5</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2000526" linkType="reference" linkID="2000526"&gt;2000526&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="15381">Chiesi Farmaceutici SpA</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18439">Mylan NV</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>C[C@H](Cc1ccc(cc1)OC)NC[C@@H](c2ccc(c(c2)NC=O)O)O</Smiles><Smiles>C[C@H](Cc1ccc(cc1)OC)NC[C@@H](c2ccc(c(c2)NC=O)O)O.C[C@H](Cc1ccc(cc1)OC)NC[C@@H](c2ccc(c(c2)NC=O)O)O.C(=C/C(=O)O)\C(=O)O.O.O</Smiles></StructureSmiles><Deals><Deal id="121500" title="Critical Therapeutics to copromote and market Dey's formoterol fumarate in the US "/></Deals><PatentFamilies><PatentFamily id="1033382" number="WO-02083079" title="Bronchodilating compositions and methods"/><PatentFamily id="1033382" number="EP-01381346" title="Pharmaceutical compositions containing formoterol"/><PatentFamily id="212399" number="US-09730890" title="Bronchodilating beta-agonist compositions and methods"/><PatentFamily id="212399" number="US-08623922" title="Bronchodilating beta-agonist compositions and methods"/><PatentFamily id="848341" number="US-08623922" title="Bronchodilating beta-agonist compositions and methods"/><PatentFamily id="848341" number="US-09730890" title="Bronchodilating beta-agonist compositions and methods"/><PatentFamily id="991217" number="US-08716348" title="Formoterol/steroid bronchodilating compositions and methods of use thereof"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>4</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="JP Morgan Chase Bank Na" id="1035874"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mylan NV" id="18439"/><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sumitomo Chemical Co Ltd" id="20268"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>3</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teva Pharmaceutical Industries Ltd" id="20348"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>3</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></drugRecordOutput>